Mohammed Abu Zaanona, MD
Hematology & Oncology · Santa Barbara, CANPI 1922591197
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Sanofi at 57.2% of the total. Reporting peaked in 2023 at $2,554 and has fallen 93.9% since, to $156 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 25 payments — averaging $133.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$221
- Cerapedics Inc.$156
- Janssen Scientific Affairs, LLC$136
- Exelixis Inc.$127
- Global Blood Therapeutics, Inc.$124
- plus $659 from 9 others
What the payments were for
- Consulting fees$1,49045%
- Travel & lodging$2337%
- Food & beverage$1,35941%
- Education$2447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $1,904 |
| AstraZeneca | 6 | $221 |
| Cerapedics Inc. | 1 | $156 |
| Janssen Scientific Affairs, LLC | 1 | $136 |
| Exelixis Inc. | 1 | $127 |
| Global Blood Therapeutics, Inc. | 1 | $124 |
| AbbVie | 1 | $115 |
| Sumitomo Pharma America, Inc. | 1 | $106 |
| Astellas Pharma US Inc | 1 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Dendreon Pharmaceuticals LLC | 1 | $78 |
| Incyte Corporation | 1 | $65 |
| Daiichi Sankyo Inc. | 2 | $60 |
| Beigene USA, Inc. | 1 | $29 |
| Legend Biotech USA Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,327 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 13 | $431 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Santa Barbara
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.